M J Forrest - Concepedia

Author

M J Forrest

Merck & Co., Inc., Rahway, NJ, USA (United States)

Also Known As

Forrest, M.J., M FORREST, M Forrest, M J Forrest, M. Forrest, M. J. FORREST, M. J. Forrest, M.J Forrest, M.J. Forrest, Marion Forrest

Publications

2.6K

Citations

H-Index

Concepts

All Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)Royal North Shore Hospital Cytel (United States)University of California San Diego Northern General Hospital

About

M J Forrest is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, inflammation, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	17	1.4K
2	Health Sciences	5	5	264
3	Allergy	4	4	194
4	Natural Sciences	1	1	426
5	Anesthesia	1	1	13

M J Forrest

Publications

2.5K

Citations

H-Index

Page 1

	Year	Citations
The discovery of rofecoxib, [MK 966, VIOXX®, 4-(4′-methylsulfonylphenyl)-3-phenyl-2(5H)-furanone], an orally active cyclooxygenase-2 inhibitor Petpiboon Prasit, Z Wang, Christine Brideau, Bioorganic & Medicinal Chemistry Letters Molecular PharmacologyMedicinal ChemistryActive Cyclooxygenase-2 InhibitorPharmaceutical ScienceBiochemistry	1999	426
Rofecoxib [Vioxx, MK-0966; 4-(4′-Methylsulfonylphenyl)-3-phenyl-2-(5 H)-furanone]: A Potent and Orally Active Cyclooxygenase-2 Inhibitor. Pharmacological and Biochemical Profiles Chi‐Chung Chan, S. Boyce, Christine Brideau, Journal of Pharmacology and Experimental Therapeutics	1999	397
Immune Cell Regulation and Cardiovascular Effects of Sphingosine 1-Phosphate Receptor Agonists in Rodents Are Mediated via Distinct Receptor Subtypes M J Forrest, S.-Y. Sun, Richard Hajdu, Journal of Pharmacology and Experimental Therapeutics	2004	332
Torcetrapib‐induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone M J Forrest, Daniel M. Bloomfield, Richard J. Briscoe, British Journal of Pharmacology	2008	283
Sialyl Lewisx-containing oligosaccharide attenuates myocardial reperfusion injury in cats. Michael Buerke, Andrew S. Weyrich, Ze‐Yi Zheng, Journal of Clinical Investigation GlycobiologyCardiovascular PharmacologyPharmacotherapyInflammationPmn Accumulation	1994	176
A selective human beta3 adrenergic receptor agonist increases metabolic rate in rhesus monkeys. M. H. FISHER, A Amend, Tom Bach, Journal of Clinical Investigation Metabolic RateObesityMolecular PharmacologyMetabolic SyndromeAdrenal Gland	1998	115
Microvascular oxidative stress preceding leukocyte activation elicited by in vivo nitric oxide suppression Makoto Suematsu, Takuya Tamatani, F. A. DeLano, American Journal of Physiology-Heart and Circulatory Physiology Leukocyte ActivationCell AdhesionLipid PeroxidationImmunologyCell Death	1994	105
Differing roles for platelet-activating factor during inflammation of the lung and subarachnoid space. The special case of Streptococcus pneumoniae. Carmen Cabellos, D. Euan MacIntyre, M J Forrest, Journal of Clinical Investigation Inflammatory Lung DiseaseLung InflammationImmunologyPaf EffectsPlatelet-activating Factor	1992	97
Human C5a des Arg increases vascular permeability. Peter J. Jose, M J Forrest, Timothy J. Williams The Journal of Immunology InflammationVascular PermeabilityMolecular PhysiologyAllergyMedicine	1981	89
Impaired leukocyte-endothelial cell interaction in spontaneously hypertensive rats. Hidekazu Suzuki, Geert W. Schmid‐Schönbein, Makoto Suematsu, Hypertension HypertensionImmunologyRenal InflammationHypertension SyndromeCellular Physiology	1994	69

Page 1